Avid Bioservices, Inc.: directors' dealings · United States · SEC (Form 4)

About Avid Bioservices, Inc.

Avid Bioservices, Inc. (ticker: CDMO) is a United States-based biologics contract development and manufacturing organization (CDMO) focused on mammalian protein development and CGMP manufacturing. For investors, it sits in the healthcare/pharma supply-chain segment and is quoted on the NASDAQ market in the United States. The company’s core proposition is to help biotechnology and pharmaceutical clients move biologic programs from early development through clinical supply and commercial manufacturing, with an emphasis on process development, analytical development, technology transfer, and reliable contract manufacturing. ([avidbio.com](https://avidbio.com/company/?utm_source=openai)) Avid’s roots go back to 1993, when biologics activity began within Peregrine Pharmaceuticals. The Avid Bioservices subsidiary was formed in 2002, the first manufacturing client was signed in 2003, and the company received its first FDA commercial approval in 2005. In 2018, Avid became a dedicated independent biologics manufacturer. A major corporate milestone followed in 2025, when the company was acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction, taking Avid private and setting the stage for a new growth phase. ([avidbio.com](https://avidbio.com/company/?utm_source=openai)) Operationally, Avid positions itself as a full-lifecycle partner for mammalian protein biologics. Its service portfolio includes cell line development, upstream and downstream process development, analytical method development and qualification, early-phase support, CGMP clinical manufacturing, and commercial-scale drug substance production. The company highlights more than 30 years of experience, more than 600 batches produced, more than 325 clinical batches, more than 275 commercial batches, and more than 20,000L of single-use bioreactor capacity. It also emphasizes a strong regulatory track record, with more than 20 years of successful inspection history and approved-manufacturer status for products marketed in more than 90 countries. ([avidbio.com](https://avidbio.com/cdmo-solutions/quality-and-regulatory-services/)) From a competitive standpoint, Avid is not a broad diversified CDMO; rather, it is a niche biologics specialist. That specialization can be attractive to sponsors seeking technical depth, quality discipline, and responsive project management in a market where execution risk is high and supply continuity matters. Its facilities are located in Orange County, California, giving it proximity to a meaningful U.S. biotech hub and supporting its positioning as a domestic manufacturing partner for companies considering reshoring, supply-chain de-risking, or accelerated development timelines. ([avidbio.com](https://avidbio.com/wp-content/uploads/2023/12/Avid-Bioservices-Investor-Presentation.pdf?utm_source=openai)) Recent news suggests management is actively reinforcing commercial and operational capabilities. In January 2026, Avid appointed Rich McAvoy as Chief Business Officer to support growth strategy and execution. In February 2026, the company opened a new Early Phase Center of Excellence in Costa Mesa, a 78,000-square-foot facility designed to expand development capacity and create a smoother path from early clinical work to commercial manufacturing. In May 2026, Avid appointed Kerri McCullough Wood as Chief Commercial Officer to lead global commercial strategy across early- and late-phase programs. These developments point to a company investing in capacity, leadership, and commercial reach within the United States biologics CDMO market. ([avidbio.com](https://avidbio.com/news/avid-bioservices-appoints-rich-mcavoy-as-chief-business-officer/?utm_source=openai))